Xenetic Biosciences, Inc. (XBIO) Stock Price & Analysis

Xenetic Biosciences, Inc. (XBIO) fell 1.68% to USD 2.64 as of July 25, 2026 at 02:25 UTC, according to Nexqual real-time market data.

XBIO last closed at USD 2.69; the session ranged USD 2.45–2.73 on volume of 56,274 shares. Market capitalization is $6.05M, with a 52-week range of USD 1.9–13.93 (NCM). Source: Nexqual, July 25, 2026 at 02:25 UTC.

Key Statistics (as of July 25, 2026 at 02:25 UTC)

Technical Analysis (XBIO)

Nexqual's technical model rates XBIO "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:25 UTC.

Earnings (XBIO)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 02:25 UTC.

Financials & Fundamentals (XBIO)

Source: Nexqual, July 25, 2026 at 02:25 UTC.

Ownership (XBIO)

Source: Nexqual, July 25, 2026 at 02:25 UTC.

From Xenetic Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• We have not been actively pursuing development efforts for XCART or PolyXen or any of our other technologies.     Research, Outside Services and Collaborations   Through partner efforts, we are developing our pipeline of next-generation bio-therapeutics and novel oncology drugs based on our DNase proprietary technology.
• We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of oncology.
• Regulation   Drug Development Process   In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act ("FDCA"), and in the case of biologics, also under the Public Health Service Act and the FDCA, and their implementing regulations.
• The first developer to receive FDA marketing approval for an orphan drug is entitled to a seven-year exclusive marketing period in the U.S. for that product.

Partnerships

• All other terms of the Scripps Agreement remain unchanged.   Effective May 1, 2025, we entered into a Third Amendment to the Scripps Agreement with Scripps Research (the "Third Amendment"), pursuant to which we expanded the services to be performed under the Scripps Agreement and provided Scripps Research additional funding in an aggregate amount of up to approximately $0.4 million to fund continuing research.
• The conduct of several CAR T in vivo models has been a primary focus of our Scripps collaboration.   We have partnered with biotechnology and pharmaceutical companies to develop our proprietary drug delivery platform, PolyXen, and receive royalty payments under an exclusive license arrangement in the field of blood coagulation disorders.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:25 UTC. This page is informational and not investment advice.